Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium
Emerging Infectious Diseases, ISSN: 1080-6059, Vol: 23, Issue: 5, Page: 809-812
2017
- 137Citations
- 95Captures
- 155Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations137
- Citation Indexes130
- 130
- CrossRef127
- Policy Citations7
- Policy Citation7
- Captures95
- Readers95
- 95
- Mentions155
- News Mentions151
- News151
- Blog Mentions4
- Blog4
Most Recent Blog
SpeeDx and Cepheid Announce Test Partnership
SpeeDx tests will be available through Cepheid’s FleXible Cartridge programme for the GeneXpert System SYDNEY-Wednesday 17 April 2019 [ AETOS Wire ] (BUSINESS WIRE)-- SpeeDx
Most Recent News
شركة سبيدإكس الخاصة المحدودة تجمع 15 مليون دولار أمريكي إضافي في جولة التمويل الثانية من الفئة بي
Link to Story سيدني -الأربعاء 12 فبراير 2020 [ AETOS Wire ] ( بزنيس واير ): أعلنت اليوم شركة "سبيدإكس" الخاصة المحدودة المتخصصة في تطوير
Article Description
Escalating resistance to azithromycin and moxifloxacin is being reported for Mycoplasma genitalium in the Asia-Pacific region. Analyzing 140 infections, we found pretreatment fluoroquinolone-resistance mutations in parC (13.6%) and gyrA (5%). ParC S83 changes were associated with moxifloxacin failure. Macrolide/fluoroquinolone-resistance mutations were in 8.6% of specimens, for which recommended therapies would be ineffective.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85018628132&origin=inward; http://dx.doi.org/10.3201/eid2305.161745; http://www.ncbi.nlm.nih.gov/pubmed/28418319; http://wwwnc.cdc.gov/eid/article/23/5/16-1745_article.htm; https://dx.doi.org/10.3201/eid2305.161745; https://wwwnc.cdc.gov/eid/article/23/5/16-1745_article
Centers for Disease Control and Prevention (CDC)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know